ATE524196T1 - An das krebsassoziierte antigen cd46 bindende antikörper und verwendungsverfahren dafür - Google Patents

An das krebsassoziierte antigen cd46 bindende antikörper und verwendungsverfahren dafür

Info

Publication number
ATE524196T1
ATE524196T1 AT02801760T AT02801760T ATE524196T1 AT E524196 T1 ATE524196 T1 AT E524196T1 AT 02801760 T AT02801760 T AT 02801760T AT 02801760 T AT02801760 T AT 02801760T AT E524196 T1 ATE524196 T1 AT E524196T1
Authority
AT
Austria
Prior art keywords
cancer
associated antigen
antibodies binding
antigen
mpa7
Prior art date
Application number
AT02801760T
Other languages
English (en)
Inventor
Jennie Mather
Original Assignee
Macrogenics West Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics West Inc filed Critical Macrogenics West Inc
Application granted granted Critical
Publication of ATE524196T1 publication Critical patent/ATE524196T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT02801760T 2001-10-16 2002-10-16 An das krebsassoziierte antigen cd46 bindende antikörper und verwendungsverfahren dafür ATE524196T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32964401P 2001-10-16 2001-10-16
PCT/US2002/033116 WO2003032814A2 (en) 2001-10-16 2002-10-16 Antibodies that bind to cancer-associated antigen cd46 and methods of use thereof

Publications (1)

Publication Number Publication Date
ATE524196T1 true ATE524196T1 (de) 2011-09-15

Family

ID=23286361

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02801760T ATE524196T1 (de) 2001-10-16 2002-10-16 An das krebsassoziierte antigen cd46 bindende antikörper und verwendungsverfahren dafür

Country Status (6)

Country Link
US (2) US7148038B2 (de)
EP (1) EP1441766B1 (de)
JP (1) JP4347694B2 (de)
AT (1) ATE524196T1 (de)
CA (1) CA2463927A1 (de)
WO (1) WO2003032814A2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1441766B1 (de) 2001-10-16 2011-09-14 MacroGenics West, Inc. An das krebsassoziierte antigen cd46 bindende antikörper und verwendungsverfahren dafür
MXPA05000778A (es) * 2002-07-18 2005-08-29 Helix Biopharma Corp Uso de ureasa para inhibir el crecimiento de celulas cancerosas.
US7264800B2 (en) * 2002-07-18 2007-09-04 Helix Biopharma Corporation Method and composition for inhibiting cancer cell growth
US20050226873A1 (en) * 2003-09-30 2005-10-13 Del Priore Lucian V Medical devices and methods for modulating cell adhesion
AR046833A1 (es) * 2003-11-10 2005-12-28 Schering Corp Anticuerpos anti-interleuquina-10
WO2005093063A1 (ja) * 2004-03-29 2005-10-06 Medical & Biological Laboratories Co., Ltd. 固形癌診断キット及び固形癌治療用医薬
GB0425972D0 (en) * 2004-11-25 2004-12-29 Celltech R&D Ltd Biological products
EP2109668A4 (de) * 2007-01-22 2011-10-05 Macrogenics West Inc Menschliche krebsstammzellen
EP2192922A4 (de) 2007-09-17 2010-09-29 Univ California Auf prostatazellen in situ abzielende internalisierende humane monoklonale antikörper
ES2733067T3 (es) 2008-12-19 2019-11-27 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
PH12018501083A1 (en) 2010-03-04 2019-02-18 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
MX339622B (es) 2010-08-02 2016-06-02 Macrogenics Inc Diacuerpos covalentes y sus usos.
WO2012031273A2 (en) 2010-09-03 2012-03-08 Stem Centrx, Inc. Novel modulators and methods of use
SG189212A1 (en) * 2010-09-03 2013-05-31 Stem Centrx Inc Identification and enrichment of cell subpopulations
US9778264B2 (en) 2010-09-03 2017-10-03 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations
US8642951B2 (en) 2011-05-04 2014-02-04 Agilent Technologies, Inc. Device, system, and method for reflecting ions
EA201391753A1 (ru) 2011-05-21 2014-08-29 Макродженикс, Инк. Домены, связывающиеся с деиммунизованной сывороткой, и их применение для увеличения времени полужизни в сыворотке
US9567402B2 (en) * 2013-03-14 2017-02-14 The Regents Of The University Of California Internalizing human monoclonal antibodies targeting prostate and other cancer cells
WO2015007887A1 (en) * 2013-07-19 2015-01-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of a ligand of hvem and an immunotoxin for use in therapy
KR102171496B1 (ko) 2013-12-05 2020-10-30 알에프이엠비 홀딩스, 엘엘씨 면역 요법을 위한 보조 메커니즘으로서의 고주파 전기막 파괴(rf-emb)에 의한 암 항원의 항원표출세포로의 개선된 표출 시스템
SG10201913680PA (en) 2014-05-29 2020-03-30 Macrogenics Inc Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
KR102559731B1 (ko) 2014-09-12 2023-07-25 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 대음세포작용 인간 항-cd46 항체 및 표적화된 암 치료제
JP6723249B2 (ja) 2015-01-30 2020-07-15 アールエフイーエムビー ホールディングス リミテッド ライアビリティ カンパニー 軟部組織を切除するためのシステムおよび方法
AU2016298227B9 (en) 2015-07-30 2019-10-31 Macrogenics, Inc. PD-1-binding molecules and methods of use thereof
JP6955507B2 (ja) 2015-12-14 2021-10-27 マクロジェニクス，インコーポレーテッド Ｐｄ‐１及びｃｔｌａ‐４との免疫応答性を有する二重特異性並びにその使用方法
TWI911597B (zh) 2016-01-15 2026-01-11 美商Ｒｆｅｍｂ控股有限公司 癌症之免疫治療
CN105462935B (zh) * 2016-01-20 2017-08-04 潘世扬 抗卵巢癌单克隆抗体及其应用
WO2018089829A1 (en) 2016-11-10 2018-05-17 Fortis Therapeutics, Inc. Cd46-specific effector cells and uses thereof
WO2018089807A2 (en) 2016-11-11 2018-05-17 The Regents Of The University Of California Anti-cd46 antibodies and methods of use
JP7132232B2 (ja) 2017-02-24 2022-09-06 マクロジェニクス，インコーポレーテッド Ｃｄ１３７及び腫瘍抗原に結合できる二重特異性結合分子並びにその使用
JP2021505637A (ja) 2017-12-12 2021-02-18 マクロジェニクス，インコーポレーテッド 二重特異性ｃｄ１６結合分子、及び疾患の治療におけるその使用
SG11202007572VA (en) 2018-02-15 2020-09-29 Macrogenics Inc Variant cd3-binding domains and their use in combination therapies for the treatment of disease
AU2021320333A1 (en) 2020-08-07 2023-03-30 Fortis Therapeutics, Inc. Immunoconjugates targeting CD46 and methods of use thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5496550A (en) 1986-08-14 1996-03-05 Chilwalner Method of reducing the output of Eimeria oocysts from a newborn chick
EP0300213A1 (de) 1987-06-22 1989-01-25 Hexal-Pharma Gentechnik GmbH & Co. KG Virale, immunogen wirksame Peptidpartikel von Hepatitis A
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5514787A (en) 1989-07-21 1996-05-07 Washington University DNA sequences encoding human membrane cofactor protein (MCP)
JP2750220B2 (ja) 1989-07-21 1998-05-13 ワシントン ユニバーシティ 組換え産生したヒト細胞膜補助因子タンパク（ｍｃｐ）
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5846715A (en) 1990-05-11 1998-12-08 The Austin Research Institute CD46 variants
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
JP3919830B2 (ja) 1992-11-28 2007-05-30 財団法人化学及血清療法研究所 抗ネコヘルペスウイルス−１組換え抗体および該抗体をコードする遺伝子断片
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
CA2153165C (en) 1993-01-14 2003-05-06 Hiroaki Maeda Recombinant anti-hiv antibody and process for preparing the same
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5665570A (en) 1994-02-10 1997-09-09 Takeda Chemical Industries, Ltd. Antibody-encoding recombinant DNA and its use
WO1997035016A1 (en) 1996-03-18 1997-09-25 Novo Nordisk Biotech Inc Polypeptides having phytase activity and nucleic acids encoding same
CN1209837A (zh) 1996-10-18 1999-03-03 财团法人阪大微生物病研会 用于轮状病毒感染的轮状病毒属抗原、疫苗和诊断试剂以及用于产生抗原的方法
WO1998034635A1 (en) * 1997-02-07 1998-08-13 The Wistar Institute Methods and compositions for the inhibition of interleukin-12 production
CN1044092C (zh) * 1997-02-26 1999-07-14 上海医科大学 抗原－抗体－重组dna复合型疫苗
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
US20030129677A1 (en) * 2000-05-12 2003-07-10 Martens Mark G. Diagnostic method for screening complement regulatory protein levels
WO2001088537A1 (en) 2000-05-12 2001-11-22 Martens Mark G Diagnostic method for screening complement regulatory protein levels
US20020115065A1 (en) * 2000-08-28 2002-08-22 Ton Logtenberg Differentially expressed epitopes and uses thereof
EP1184458A1 (de) * 2000-08-28 2002-03-06 U-BISys B.V. Unterschiedlich exprimierte CD46 Epitope, proteinartige Moleküle die fähig sind daran zu binden, und deren Verwendungen
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
EP1441766B1 (de) 2001-10-16 2011-09-14 MacroGenics West, Inc. An das krebsassoziierte antigen cd46 bindende antikörper und verwendungsverfahren dafür
WO2003101187A1 (en) * 2002-05-30 2003-12-11 Raven Biotechnologies, Inc. Animal model for toxicology and dose prediction
JP2006515318A (ja) * 2002-10-29 2006-05-25 ファルマシア・コーポレーション 特異的に発現する癌関連遺伝子、それによってコードされるポリペプチドおよびその使用方法
JP2008523083A (ja) * 2004-12-08 2008-07-03 イムノメディクス， インコーポレイテッド 炎症性疾患および免疫調節不全疾患、感染性疾患、病的血管新生およびがんの免疫療法および検出のための方法および組成物

Also Published As

Publication number Publication date
EP1441766A4 (de) 2006-03-08
EP1441766A2 (de) 2004-08-04
HK1064621A1 (en) 2005-02-04
JP4347694B2 (ja) 2009-10-21
US20030108966A1 (en) 2003-06-12
WO2003032814A3 (en) 2003-09-12
CA2463927A1 (en) 2003-04-24
EP1441766B1 (de) 2011-09-14
US7148038B2 (en) 2006-12-12
WO2003032814A2 (en) 2003-04-24
JP2005511525A (ja) 2005-04-28
US20070128202A1 (en) 2007-06-07
US7744878B2 (en) 2010-06-29

Similar Documents

Publication Publication Date Title
EP1441766A4 (de) An das krebsassoziierte antigen cd46 bindende antikörper und verwendungsverfahren dafür
NO20074474L (no) Antistoffer som binder til EPHA2 og fremgangsmate for anvendelse derav
WO2003024191A3 (en) Antibodies that bind to cancer-associated antigen cytokeratin 8 and methods of use thereof
DK1565489T3 (da) Internaliserende antistoffer specifikke for RAAG10-celleoverflademålet
DE69433663D1 (de) Antikörper gegen menschliches prostatspezifisches drüsenkallikrein
DE602006013029D1 (de) Anti-egfr-antikörper
TR200202799T3 (tr) AB peptidini sekanslayan insanlaştırılmış antikorlar
NO20054351L (no) Monoklonalt antistoff og hybridom som produserer dette
TW200510459A (en) RG1 antibodies and uses thereof
DE69940436D1 (de) Prostata stammzellantigen (psca) und dessen verwendungen
EA200401198A1 (ru) АНТИТЕЛА ПРОТИВ αvβ6
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
TR200103756T2 (tr) Hümanize anti-ErbB2 antikorları ve anti-ErbB2 antikorlarıyla tedavi.
ATE303161T1 (de) Humanisierung von anti-carcinoembryonalen antigen anti-idiotypischen antikörper und dessen verwendung als tumorvakzin und zur markierung
MXPA06010673A (es) Reduccion del riesgo de anticuerpos humanos anti-humano a traves de manipulacion del gen v.
ATE459706T1 (de) Monoklonales antikörper gegen das hcv kernantigen
SG146644A1 (en) Kid3 and kid3 antibodies that bind thereto
WO2003087340A3 (en) Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
WO2004043239A3 (en) Antigen pipa and antibodies that bind thereto
WO2003064593A3 (en) Antigen panels and methods of using the same
WO2002072008A3 (en) Method for treating cancer using a33 specific antibodies and chemotherapeutic agents
DE60113968D1 (de) Diagnose von brustkrebs unter verwendung von bcmp-7 als marker
WO2004101762A3 (en) Detection and treatment of cancers of the colon
WO2003024302A3 (en) Detection and treatment of cancers of breast
NO20004251L (no) Humaniserte anti-CEA monoklonale antistoffer med høy affinitet

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties